The trends for APOA1 were found to be opposite in Gliomas and Meningiomas, with higher expression in GBMs and Grade I meningiomas as compared to the LGGs and Grade II meningiomas, respectively. This evidence concerns the gene APOA1 and central nervous system cancer.